• Turning Breakthrough
  • Discoveries  into Medicines

About Us

About Us

1ST Bio is dedicated to developing breakthrough therapies with a key value to provide novel medicines to patients. We are focused on discovery and development of innovative first-in-class therapeutic candidates with highly likelihood of clinical success. 1ST Bio currently has 16 employees with expertise in biochemistry, medicinal chemistry, pharmacology, and business development. We are working as a core expertise team of drug discovery/development and are rigorously connected to R&D networking of academia, hospitals, industry, CRO’s and investors in Korea, China and US. Our ultimate goal is to use our experience and knowledge to discover and develop effective molecular therapeutics for patients.

Therapeutic Focus

Therapeutic Focus

Neurodegenerative Diseases


Orphan diseases



1ST-102 targets c-Abl, which has been shown to play a critical role in driving alpha-synuclein pathogenesis in Parkinson’s disease. Our current candidate has optimal properties as CNS drug with potent neuroprotection activities and desirable safety profiles. We expect to file phase I IND in 2018 and we believe that it will be the first c-Abl inhibitor to advance into clinical trials, with optimal target engagement, CNS behaviors and safety profiles necessary for treatment of Parkinson’s disease with high potential as disease-modifying agent.

1ST-101 and 1ST-103 are in discovery stage as approaches to inhibit neuroinflammation associated with various neurodegenerative diseases. 1ST-101 and 1ST-103 block a critical pathway in vicious inflammatory response followed by neurotoxicity, which leads to disease-modifying potential and broad-spectrum therapeutic options for Parkinson’s, Alzheimer’s and ALS.

1ST-201 targets a crucial pathway in immuno-oncology and aims to reverse the active immune suppression and stimulate functionality of effector immune cells and dendritic cells in tumor microenvironment. We envision that 1ST-201 will provide novel therapeutic option as well as beneficial part of combination in immunotherapy with the objective of modulating multiple therapeutic opportunities for maximum benefits to cancer patients.



美뉴랄리와 파킨슨치료제 공동개발 협약

뉴랄리에서 후보물질에 대한 전임상 동물실험 진행…내년 FDA 임상승인 신청 목표

2018년 04월 30일0 comment

시리즈B 190억 유치

파킨슨병 치료제 후보물질 및 후속 프로젝트 연구개발에 투입, 면역항암제 특화된 자회사 티오바이오(TIO...

0 comment


BioCentury reprint from January 22, 2018 COMPUTING BRAIN ENTRY Emerging Company Profile...

2018년 02월 15일0 comment



Let's Fulfill Unmet Medical Needs Together!

주식회사 퍼스트바이오 테라퓨틱스

경기도 성남시 분당구 판교역로 240 (삼환하이펙스 A동)

313호 (본사)

306호 (연구소)


1ST Biotherapeutics, Inc.

240 Pangyoyeok-ro, Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea

Suite 313 (HQ)

Suite 306 (R&D)


(031) 8023-5332 Main 
(031) 8023-5333 Fax